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Self-reported quality of life
(QOL) was prospectively
measured from phase 2 trials
of stereotactic body radiation
therapy for prostate cancer.
Transient decline in urinary/
bowel domains within 3
months returned to baseline
or better within 6 months and
remained so. The same
pattern was observed with
good versus poor baseline
function and was indepen-
dent of early toxicities.
Sexual QOL decline was
predominantly observed
within 9 months and not
altered by androgen depriva-
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http://dx.doi.org/10.1016/j.ijrobp.2013.08.019Purpose: To evaluate the early and late health-related quality of life (QOL) outcomes among
prostate cancer patients following stereotactic body radiation therapy (SBRT).
Methods and Materials: Patient self-reported QOL was prospectively measured among 864
patients from phase 2 clinical trials of SBRT for localized prostate cancer. Data from the
Expanded Prostate Cancer Index Composite (EPIC) instrument were obtained at baseline and
at regular intervals up to 6 years. SBRT delivered a median dose of 36.25 Gy in 4 or 5 fractions.
A short course of androgen deprivation therapy was given to 14% of patients.
Results: Median follow-up was 3 years and 194 patients remained evaluable at 5 years. A tran-
sient decline in the urinary and bowel domains was observed within the first 3 months after
SBRT which returned to baseline status or better within 6 months and remained so beyond
5 years. The same pattern was observed among patients with good versus poor baseline function
and was independent of the degree of early toxicities. Sexual QOL decline was predominantly
observed within the first 9 months, a pattern not altered by the use of androgen deprivation
therapy or patient age.
Conclusion: Long-term outcome demonstrates that prostate SBRT is well tolerated and has little
lasting impact on health-related QOL. A transient and modest decline in urinary and bowel QOL
during the first few months after SBRT quickly recovers to baseline levels. With a large number
of patients evaluable up to 5 years following SBRT, it is unlikely that unexpected late adverse
effects will manifest themselves.
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King et al. International Journal of Radiation Oncology  Biology  Physics940Introduction RapidArc technique on a Novalis Tx (Varian Medical SystemsThe evolution of radiation therapy technology over the past
2 decades, which integrates 3-dimensional anatomy, conformal
dose coverage, and image guidance combined with a deeper
appreciation of the radiobiology of prostate cancer, has led to
hypofractionated radiation therapy schedules. Consequently,
substantial clinical data now exist from several studies including
randomized trials using various moderately hypofractionated
regimens, with dose-per-fraction ranging from 2.5 Gy per fraction
for 70 Gy and 3.1 Gy per fraction for 62 Gy (1-9) and, more
recently, extreme hypofractionation schemes of 7.25 Gy per
fraction for 36.25 Gy to 10 Gy for 50 Gy (10-16) using stereo-
tactic body radiation therapy (SBRT) approaches. Hypofractio-
nation for prostate cancer, and in particular SBRT, results in
a means of radiobiological dose escalation and potentially repre-
sents a therapeutic gain. It also affords a more economical course
of definitive radiation therapy, improves patient access to care, and
enhances patient convenience.
So far, data from published prostate SBRT trials have shown
late grade 3 gastrointestinal and gastrourinary toxicities to lie
within a 1%-3% range (10-16). Lacking, however, is an assess-
ment of long-term quality of life (QOL) outcomes after prostate
SBRT. In 2011, we formed a consortium for prostate SBRT with
a 2-fold purpose: first to analyze all of the currently available
clinical data and second to establish a centralized center for
prospective data acquisition and analysis accessible to all current
and future eligible centers. In an earlier report from this consor-
tium based on 1100 patients (17), we showed 5-year prostate-
specific antigen/relapse-free survival rates of 95%, 84%, and
81% for low-, intermediate-, and high-risk patients, respectively
(P<.001). The current study from this consortium pools previously
unpublished prospective data into a sufficiently large dataset and
over a long enough follow-up period to provide a benchmark
regarding the long-term health-related QOL outcomes following
SBRT for prostate cancer.Methods and Materials
Patients
In the present study, patients enrolled in separate Institutional
Review Board-approved prospective phase 2 clinical trials and
prospective protocols of prostate SBRT from 4 centers were
pooled, yielding 864 patients treated between the years 2005 and
2012 (nb: this cohort is a subset of the 1100 patients of our
publication on outcomes and is limited to those institutions with
complete QOL data) (17). A separate Institutional Review Board
for centralized data collection and analysis was obtained at this
academic institution. Eligible patients had biopsy-proven newly
diagnosed, nonmetastatic and untreated prostate cancer. For each
trial, the endpoints included early and late urinary and rectal
toxicities, questionnaire-based QOL measures with a validated
instrument and prostate-specific antigen response.
Treatment
Fiducial-based image-guided SBRT was delivered with either the
CyberKnife (Accuray Inc, Sunnyvale, CA) or with linac-basedInc, Palo Alto, CA). The treatment specifics from individual
centers have been published previously (10-13). Differences
among the 4 centers were relatively minor and primarily centered
around dose, dosimetry, and dose fractionation. The course of
radiation therapy consisted of a median homogeneous dose of
36.25 Gy (range 35-40 Gy) over 5 fractions for 84% of patients,
and a median heterogeneous dose of 39 Gy in 4 fractions for the
remaining 16%. For the homogenous planning, dose was
normalized around thew90% isodose line on average in order for
the prescription dose to cover at least 95% of the planning target
volume. Generally speaking, doseevolume histogram (DVH)
goals for the rectum were such that the V50% <50% (ie, the
volume receiving 50% of the prescribed dose was <50%), V80%
<20%, V90% <10%, and V100% <5%. The bladder DVH goals
were V50% <40% and V100% <10%. The femoral head DVH
goal was V40% <5%.
A short course (median 4 months) of neoadjuvant and
concurrent androgen deprivation therapy (ADT) was allowed at
the discretion of the treating physician and given to 14% of
patients.
Data collection, follow-up, and analysis
The Expanded Prostate Cancer Index Composite (EPIC) was
used in each center (18). EPIC is a validated QOL instrument
that consists of a set of 26 questions scoring urinary, bowel, and
sexual domains. The resulting domain scores are then translated
into a 0 to 100 scale, with higher values representing a more
favorable health-related QOL or outcome satisfaction. Patient
self-reported data were prospectively acquired at baseline and
prospectively at 1, 2, and 3 months after SBRT and subsequently
at 3- to 6-month intervals. A clinically relevant change in the
QOL (or a minimum important change) was defined as a differ-
ence from baseline to follow-up that exceeded half a standard
deviation of the baseline value as used in similar studies (19, 20).
To compare the impact on QOL for patients with differing
baseline characteristics a comparison was made between patients
in the top 25th percentile versus the bottom 75th percentile for
each domain. Similarly, to compare the impact on QOL for
patients as a function of early toxicities (ie, within the first 3
months after SBRT), patients were stratified into quartiles based
on the degree of their early decline in QOL for each domain.
Lastly, to evaluate the outcomes on those patients with the
poorest baseline function, the worst fifth percentile were identi-
fied and studied over time.
Results
The number of complete EPIC questionnaires available as a func-
tion of follow-up time is given in Table 1. The median follow-up for
the 864 patients was 36 months, with 194 patients remaining
evaluable out to 5 years. Median patient age was 69 7.7 years. At
baseline, the mean EPIC score for urinary and bowel domains
revealed good baseline function with a narrow spread, 89 12 and
95  9, respectively, whereas for the sexual domain, it was
consistent with the expectations for this age group, with a mean
EPIC score 53  28. Health-related QOL was evaluated as the
change in score over time, stratified according to baseline function,
use of ADT, or age at treatment. The mean change in EPIC scores
Table 1 Mean baseline Expanded Prostate Cancer Index Composite scores and change over time relative to baseline for all patients
following prostate stereotactic body radiation therapy
Time Number of patients Urinary domain Bowel domain Sexual domain
Baseline 864 89  12 95  9 53  28
1-3 mo 826 8.7 [9.5 to 7.8] 12 [13.1 to 11] 5.1 [6.5 to 3.7]
6 mo 500 0.95 [1.9 to 0.01] 3.5 [4.5 to 2.5] 4.2 [5.8 to 2.5]
9 mo 388 2.9 [4.1 to 1.7] 4.0 [5.1 to 2.9] 6.1 [8.1 to 4]
12 mo 658 2.5 [3.4 to 1.6] 3.2 [4.2 to 2.3] 5.5 [7 to 4]
24 mo 489 0.6 [1.5 to 0.3] 1.1 [2 to 0.2] 6.1 [7.9 to 4.4]
36 mo 388 0.4 [0.6 to 1.3] 0.85 [2.2 to 0.5] 7.3 [9.3 to 5.3]
48 mo 271 1.9 [0.9 to 2.8] 0.6 [0.3 to 1.4] 10.6 [12.4 to 8.7]
60 mo 194 1.8 [0.7 to 2.9] 0.9 [0 to 1.9] 13.1 [14.9 to 11.3]
72 mo 63 2.3 [0.9 to 3.7] 1.8 [0.6 to 3] 13.7 [16.2 to 11.1]
Negative values indicate a decline and positive values indicate an improvement over baseline scores. The 95% confidence interval is given in brackets.
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urinary and bowel QOL, a decline was most notable within the first
3months, which hadmostly recovered by 6months, remained stable
and actually showed improvement over baseline starting at around
3 years. For the sexual domain, the observeddecline remained stable
out to 2 years and thereafter declined progressively for the duration
of follow-up. Graphically, change in QOL is shown in Figure 1 for
the domains of urinary, bowel, and sexual function. A significant but
modest decline in urinary QOL is observed within the first 3 months
after SBRT, which had nearly returned to baseline approximately
6 months after treatment. For those patients with poorer function at
baseline (in lower 25th percentile), a gradual improvement in
urinary QOL was in fact observed beginning 6 months after treat-
ment and progressing to better than baseline function over the
6 years spanned by the available data. No differenceswere seenwith
the addition of ADT or as a function of patient age. A similar trend
was seen for bowel QOL, where a significant decline occurs within
the first 3 months after SBRT that subsequently returned to baseline
levels approximately 6 months after. A gradual improvement over
baseline was also observed for those patients who start off with
poorer baseline QOL (in lower 25th percentile). Again, therewas no
impact from the addition of ADT nor with age.
For patients reporting good baseline function (in the top 75th
percentile with a mean EPIC sexual QOL score of 66), sexual QOL
is observed to decline predominantly within the first 9 months and
subsequently at a steadily slow rate out to 6 years. For patients with
the poorest baseline function (in lower 25th percentile with a mean
EPIC score of 13), there is little significant change in their poor
baseline sexual QOL over time. The impact of ADTon sexual QOL
occurs primarily within a 3- to 9-month timeframe after SBRT,
returning to baseline by 12 months after treatment, which is likely
a consequence of testosterone recovery. The rate of subsequent
decline parallels that of patients who did not receive ADT. Age at
treatment does not appear to have an impact on the effect of SBRT
because the 2 curves remain parallel out to 6 years.
The degree to which “early” QOL decline (ie, defined as 1- to
3-months post-SBRT) influences the time to recover or the late
function for each domain was studied by stratifying the early
response into 4 distinct quartiles. The results are shown in
Figure 2. For the urinary and bowel domains, those patients with
the worst early problems (in lower 25th and 25th-50th percentile
groups) recovery to near baseline levels was seen within 9 to 12
months. Thereafter, all groups converge to their baseline levels.
For the sexual QOL domain, early response identifies thosepatients who will continue to experience issues long term, and the
4 quartile groups remain separate throughout the 6 years of
follow-up.
Lastly, we examined whether patients with the poorest baseline
function were more susceptible to lasting negative impact on their
QOL from SBRT. The results are shown in Figure 3 in which we
compare patients within the worst fifth percentile group at baseline
relative to all other patients. For urinary and bowel domains, this
worst fifth percentile group actually showed improvement above
their baseline QOL, peaking around 6 months after SBRT, and
thereafter becoming stable out to 6 years. For the sexual domain,
there was initial improvement above the baseline EPIC score for
this group (with scores near zero) that peaked around 12 months
after SBRT (EPIC score w20) and thereafter remained stable.
Discussion
The health-related QOL data accumulated thus far on 864 patients
from 4 prospective trials allows for the reporting of the long-term
clinical outcomes following prostate SBRT. The principal
conclusions were as follows: (1) the transient decline in the
urinary and bowel domains observed within the first 3 months
following SBRT returned to baseline status or better within
6 months and remained so long term; (2) the same pattern was
observed among patients with good versus poor baseline function
and was also independent of the degree of early toxicities; (3)
neither a short course of ADT nor age had an impact on urinary or
rectal QOL; and (4) for those patients experiencing sexual QOL
decline, it was predominantly observed within the first 9 months,
subsequently stabilized and declined naturally with aging,
a pattern not altered by the use of ADT nor patient age at
treatment.
Several key studies have prospectively examined the impor-
tance of health-related QOL after definitive treatment for prostate
cancer (20-23). A recent comprehensive study was that of Sanda
et al (20) reporting EPIC-based QOL after prostate IMRT, bra-
chytherapy, or surgery. That study, which followed patients out to
2 years posttreatment, showed patterns of urinary and bowel
decline in scores after IMRT of a magnitude range of 10-15 EPIC
score points, occurring at approximately 2 months post-treatment
and returning to baseline scores at approximately 6 months. Those
results are consistent with our analysis after SBRT. Similar to our
study, that study also showed that the addition of ADT was not
Fig. 1. The graphs show unadjusted mean quality of life scores over time for each domain stratified according to baseline level (top 25th
percentile vs lower 75th percentile), use of androgen deprivation therapy (ADT), or age (younger vs older than median age). Scores from
the Expanded Prostate Cancer Index Composite domains range from 0 to 100, with higher values representing a more favorable health-
related quality of life. Asterisks (*) designate time points at which scores were clinically significantly different (either worse or better)
from those at pretreatment baseline. Error bars represent 95% confidence intervals.
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decline of approximately 10 EPIC score points, peaking at around
2 months, again similar to our data after SBRT. In the Sanda study,
the addition of ADT exacerbated sexual QOL long term, but in
that study, the duration of ADT was not reported raising the
possibility that prolonged ADT contributed to long-term sexual
dysfunction. In the Pardo et al study (21), also using EPIC-based
QOL to compare radical prostatectomy (RP), external beamradiation therapy to low-dose-rate brachytherapy without use of
ADT, greater deterioration of urinary incontinence and sexual
scores but better urinary irritative-obstructive results were
observed with RP, whereas worse bowel symptoms were observed
with external beam radiation therapy. Similarly, the Katz et al
study (22) using EPIC-based QOL to compare RP with SBRT
showed that largest differences in QOL occurred within the first 6
months after treatment, with larger declines following surgery in
Fig. 2. The graphs show unadjusted changes relative to baseline
mean quality of life scores over time for each domain (urinary,
bowel, sexual) stratified into 4 quartile groups according to degree
of initial decline in quality of life score within the first 3 months
after stereotactic body radiation therapy. Error bars represent 95%
confidence intervals.
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in bowel QOL following SBRT compared with surgery. Lastly, the
Hoskin et al study (23) using the FACT-P (Functional Assessment
of Cancer TherapydProstate) QOL instrument to compare EBRT
alone or with high dose rate boost showed no differences in long-term QOL among patients randomly assigned to each treatment
arm with up to 10-year follow-up. That study is particularly
important in that it demonstrates a therapeutic advantage with
hypofractionation because biochemical disease-free survival was
superior with high dose rate boost compared with EBRT alone but
did not result in worse sequelae.
Interestingly, our observations show that urinary, bowel, and
sexual QOL recovers to better than baseline levels for the subset
of patients with poorer baseline function (ie, worst 25th or fifth
percentile). Naturally, this is not a beneficial consequence of
SBRT but can be understood within the context of optimal
management of those issues for trial patients with repeated access
to physicians over a prolonged period. The current database did
not document the use of alpha blockers, dietary modifications, or
use of PDE5I phosphodiesterase-5 inhibitor during and after
treatment, which would naturally yield improvements in QOL and
is a limitation of this study. With respect to the sexual QOL for the
age group represented by this study (median, 69 years), it is
challenging to interpret because the prevalence of erectile
dysfunction (ED) increases sharply between the ages of 60 and 70
years. In a large and recent epidemiologic study of US men, ED
was present among approximately 15% of men 40-59 years of age,
climbing to approximate 44% for men 60-69 years old, and
approximate 70% for men aged >70 years (24). The incremental
prevalence rate of ED is therefore on average 2%-3% per year.
Consequently, longitudinal studies such as ours, which span 5
years, can expect to see an approximately 10% increase in ED
measures simply from natural aging. Similarly, factors such as
cardiovascular risk, hypertension, diabetes, and smoking were not
specifically tracked in our study but are well-known factors
affecting ED even after correcting for age (24). Nevertheless, our
data clearly show that with judicious medical management the
adverse effects resulting from SBRT can be overcome and
compensated for, leading to an effective overall improvement in
QOL relative to baseline. There did not appear to be a subset of
patients in whom SBRT would be contraindicated because even
those within the worst fifth percentile baseline urinary or bowel
function were able to maintain, if not improve on, each QOL
domain.
When considering toxicities, it is challenging to separate
differences resulting from technique, that is, 3D versus IMRT
versus IGRT versus SBRT, from those resulting of dose escalation
or dose fractionation. Therefore, caution should be exercised
when comparing SBRT, which inherently adopts smaller planning
target volume margins and provides intrafraction IGRT.
Comparison with IMRT was briefly discussed earlier in the
article. To date, outcome studies following proton beam therapy
are limited in scope and duration of follow-up. A recent study
from the University of Florida Proton Therapy Institute (25)
based on 262 patients (aged 60 years) with a median follow-
up of 2 years showed a decline in EPIC scores of approxi-
mately 5 points for urinary and bowel scores, and 13 points for
sexual score at 2 years posttreatment, results that are quite similar
to those presented for SBRT.
Conclusions
After a transient decline in the first few months, the urinary and
bowel QOL following SBRT for prostate cancer quickly recovers
back to baseline levels or better within 6 months and remains so
long term. Age, use of ADT, and the degree of early toxicities had
Fig. 3. The graphs show unadjusted mean quality of life scores over time for each domain (urinary, bowel, sexual) stratified according to
patients with the worst baseline level (bottom fifth percentile) versus the remainder (top 95th percentile). Asterisks (*) designate time points
at which scores were clinically significantly different from those at pretreatment baseline. Error bars represent 95% confidence intervals.
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sexual QOL is observed within the first 9 months. With such
a large number of patients evaluable up to 5 years following
SBRT, it is unlikely that unexpected adverse effects will manifest
at later time periods. The current evidence regarding early and
long-term health-related QOL supports consideration of SBRT
among the definitive therapeutic options for localized prostate
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